THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rodwelch@pacbell.net
S U M M A R Y
DIARY: February 4, 2009 05:47 PM Wednesday;
Rod Welch
Millie receives Stritter research on treating cancer as chronic disease
after UCSF achieves local control of expanding IBC.
1...Summary/Objective
2...Treatment Options Following Hyperthermia for Chronic Cancer Care
....Treatment Options Patient Profile
..............
Click here to comment!
CONTACTS
SUBJECTS
2nd Opinion Retainer $300 Scope of Work Rceived Support Medical Tea
1803 -
1803 - ..
1804 - Summary/Objective
1805 -
180501 - Follow up ref SDS 81 0000. ref SDS 78 0000.
180502 -
180503 -
180504 -
180506 - ..
1806 -
1807 -
1808 - Background
1809 -
180901 - Prior work with Doctor Stritter is reported on 090106. ref SDS 49 KI5I
180902 - This record focuses on 2nd opinion for strategy to treat cancer as a
180903 - chronic disease after recovering from 6th relapse of IBC by achieving
180904 - local control with hyperthermia treatments at UCSF...
180905 -
180906 - 1. Millie met Doctor Stritter during
180907 - seminar presentation at Wellness
180908 - Community cancer support
180909 - group.............................. 081018, ref SDS 29 PQ6X
180911 - ..
180912 - 2. Doctor Stritter asked for copies of
180913 - correspondence with the medical team
180914 - on Millie's response to sunitinib
180915 - treatment for cancer that supports
180916 - Doctor Stritter's research on
180917 - advanced cancer
180918 - treatments......................... 081018, ref SDS 29 1Y4G
180920 - ..
180921 - 3. Doctor Stritter was helpful finding
180922 - referral for resolving payment issues
180923 - with Kaiser for Millie's treatment
180924 - on referral to UCSF................ 081114, ref SDS 33 638G
180926 - ..
180927 - 4. Millie was confused, worried, and
180928 - emotional about plans to maintain
180929 - strong recovery from cancer and reduce
180930 - side effects by adjusting treatments
180931 - to tolerable levels on 081226,
180932 - presented during meeting at
180933 - UCSF............................... 081218, ref SDS 41 QW48
180934 - as set out in the letter confirming
180935 - understandings to the medical
180936 - team............................... 081218, ref SDS 42 GF4V
180937 - Millie submitted a copy to Doctor
180938 - Stritter of the letter on 081218 to
180939 - the medical team reporting results of
180940 - examination at
180941 - UCSF............................... 081218. ref SDS 42 4P7F
180943 - ..
180944 - 5. Millie sent a copy to Doctor Stritter
180945 - of another letter to the primary care
180946 - physician at Kaiser on 081219, requesting
180947 - assistance managing the work plan at
180948 - UCSF for Millie's treatment with
180949 - sunitinib.......................... 081219, ref SDS 44 KY8Q
180950 - noting that case management is
180951 - difficult due to limited time and emotional
180952 - feelings that prevent thorough analysis
180953 - during meetings with
180954 - doctors............................ 081219, ref SDS 44 SU8X
180956 - ..
180957 - 6. Millie's letter to Doctor Stritter
180958 - requested second opinion on Millie's
180959 - treatment with sunitinib staying at
180960 - full strength and reducing or ending
180961 - treatment with cyclophosphamide
180962 - to reduce side
180963 - effects............................ 081220, ref SDS 45 I69Q
180965 - ..
180966 - 7. Millie received a letter from Doctor
180967 - Stritter with terms and conditions for
180968 - 2nd opinion, and transmitting a pdf file
180969 - requesting patient history in a
180970 - questionnaire...................... 081223, ref SDS 46 8N9M
180972 - ..
180973 - 8. Questionnaire could not be filled out
180974 - in pdf file because Adobe Acrobat
180975 - could not be configured; information
180976 - requested in the form was
180977 - entered in the
180978 - record............................. 081223, ref SDS 46 DQ6J
180980 - ..
180981 - 9. Patient history for Doctor Stritter's
180982 - 2nd opinion support was developed
180983 - in the SDS record.................. 090106, ref SDS 49 IP6H
180985 - ..
180986 - 10. Millie sent letter to Doctor Stritter
180987 - with payment of $300 for 2nd
180988 - opinion services................... 090106, ref SDS 49 S34O
180989 - and listing objectives for
180990 - conslutation....................... 090106, ref SDS 49 6H3Q
180992 - ..
180993 - 11. Doctor Stritter notified Millie that
180994 - she was attending a professional conference
180995 - on integrative oncology conference in
180996 - Florida, and would respond to
180997 - Millie's letter on
180998 - 090114............................. 090107, ref SDS 51 PJ3I ,
181000 - ..
181001 - 12. Doctor Stritter called and advised she
181002 - needs another $300 to provide a 2nd
181003 - opinion on treatments for
181004 - Millie............................. 090114, ref SDS 52 U290
181005 - doctor requested support reviewing
181006 - Millie's complex patient history
181007 - for 2nd opinion
181008 - work............................... 090114, ref SDS 52 U271
181010 - ..
181011 - 13. Millie sent a letter to Doctor Stritter,
181012 - ref SDS 55 3C5O, following up the letter
181013 - on 090106 setting out scope of assignment,
181014 - ref SDS 49 S34O, confirming understandings
181015 - from the call on 090114, and submitting
181016 - additional information on pathology
181017 - reports and CT tests requested
181018 - by the doctor...................... 090119, ref SDS 52 U271
181020 - ..
181021 - 14. Called Doctor Stritter who asked for
181022 - information in a questionaire she
181023 - submitted with a letter to Millie on
181024 - 091223, ref SDS 46 DQ6J, the doctor
181025 - wants another $300 to provide a list
181026 - of treatments that can
181027 - help Millie........................ 090120, ref SDS 56 CM66
181029 - ..
181030 - 15. Millie sent a letter to Stritter Medical
181031 - Consulting transmitting information
181032 - requested in the Questionnaire
181033 - received in the record on
181034 - 081223............................. 090121, ref SDS 57 C57O
181036 - ..
181037 - 16. Regrettably, time has become a factor
181038 - because the cancer marker jumped to
181039 - CA 15-3 303 for the lab on 090116.
181040 - ref SDS 53 PQTQ; Millie needs
181041 - input as soon as
181042 - possible........................... 090121, ref SDS 57 SC5T
181044 - ..
181045 - 17. Dislocated shoulder from fall treatment
181046 - in Emergency Department on 090122, and
181047 - notice that UCSF ended Millie's
181048 - treatment with sunitinib due to 6th
181049 - relapse of IBC, and rising side
181050 - effects; copy of letter to
181051 - medical team sent to Doctor
181052 - Stritter........................... 090123, ref SDS 60 KR4P
181054 - ..
181055 - 18. Millie letter notified Doctor Stritter
181056 - that UCSF ended treatment with sunitinib
181057 - due progression of
181058 - disease............................ 090126, ref SDS 63 Q59G
181059 - Millie meeting with UCSF on 090129
181060 - asks Doctor Stritter for
181061 - treatment options.................. 090126, ref SDS 63 066T
181063 - ..
181064 - 19. Doctor Stritter letter proposes teleon
181065 - 2nd opinion on 090203 or on 090205 at
181066 - 1600, and needs payment of another
181067 - $300 paymnet in advance of
181068 - consultation....................... 090127, ref SDS 64 L24J
181070 - ..
181071 - 20. Millie submitted payment of $300 and
181072 - requests consultation on 090203,
181073 - requests receipt................... 090127, ref SDS 64 HO5W
181075 - ..
181076 - 21. Doctor Stritter receives payment;
181077 - says cannot have telecon on 090203;
181078 - asks about having consultation
181079 - on 090205 1600..................... 090130, ref SDS 67 4W6L
181081 - ..
181082 - 22. Millie responds to Gwen's letter on
181083 - 090130, ref SDS 67 4W6L, reports cancer
181084 - is progressing [see Millie's letter to
181085 - medical team on 090130, ref SDS 68 AY7X,
181086 - and lining up treatment
181087 - options has been
181088 - difficult.......................... 090131, ref SDS 69 4W6L
181089 - and shown in the letter to the
181090 - medical team on 090130, with a copy
181091 - to Gwen. ref SDS 68 W858
181093 - ..
181094 - 23. Primary objective for Stritter Medical
181095 - is to submit research and written opinion
181096 - listing treatments for IBC, and sources
181097 - for Millie's complex patient profile,
181098 - shown in Millie's letter to
181099 - Gwen............................... 090131, ref SDS 69 H95S
181100 - Obvious question is are there
181101 - other treatments that can
181102 - help me............................ 090131, ref SDS 69 H96U
181104 - ..
181105 - 24. Agenda requested a day or so before
181106 - telecon consultation with a partial
181107 - list of possible treatments, so
181108 - people can be prepared with
181109 - focused questions.................. 090131, ref SDS 69 H96X
181111 - ..
181112 - 25. Millie receives letter from Gwen
181113 - reporting plans to submit preliminary
181114 - research on 090203 in time to be
181115 - prepared for telephone conference
181116 - on 090205 1600; recommends start
181117 - Doxil and hyperthermia
181118 - at UCSF............................ 090202, ref SDS 72 EF9M
181120 - ..
181121 - 26. Millie received letter from Gwen
181122 - transmitting preliminary research
181123 - for cancer treatments that fit Millie's
181124 - complex patient profile that requires
181125 - continuing treatment for cancer as a
181126 - chronic disease after hyperthermia and
181127 - lower dose radiation at UCSF to achieve
181128 - local control, and implements planning
181129 - presented in Gwen's letter on 090202,
181130 - ref SDS 73 EF9M, which responded to
181131 - Millie's request in a letter to
181132 - Stritter Medical Consulting on
181133 - 090131, ref SDS 70 H96X, for
181134 - an agenda to guide telecon
181135 - consultation scheduled
181136 - for 090205......................... 090203, ref SDS 78 CF7J
181138 - ..
181139 - 27. On 090204 0257 Millie notifies Gwen that preliminary report
181140 - from Stritter Medical Consulting, received on 090203 2257,
181141 - ref SDS 78 CF7J, aligns with requirements for listing possibile
181142 - treatments for Millie after hyperthermia treatment at UCSF
181143 - achieves local control of expanding IBC; provides agenda to
181144 - discuss in telecon conference on 090205 1600 strategy to
181145 - transition, when needed in a few weeks, or hopefully many
181146 - months toward treating cancer as a chronic disease. ref SDS 81
181147 - 7P9O
181149 - ..
181150 - 28. On 090204 0257 Millie's letter to Stritter Medical Consulting
181151 - asks for comment on research indicating treatment strategy
181152 - evaluating blood or tissue, ref SDS 81 FQ3W, in this case IBC
181153 - infected skin, for testing in a laboratory to discover the most
181154 - effective cancer treatment, shown in the record on 090129.
181155 - ref SDS 66 YL7G
181156 -
181157 -
181158 -
1812 -
SUBJECTS
Cancer Treatments Chronic Disease Strategy Clinical Studies Trials a
3103 -
3104 - Progress
310501 - ..
310502 - Treatment Options Following Hyperthermia for Chronic Cancer Care
310503 -
310504 - Millie receives Gwen's letter responding to Millie's letter sent
310505 - earlier this morning on 090204 0257, ref SDS 81 7P9O
310507 - ..
310508 - This is the 7th second opinion Millie has consulted to support the
310509 - medical team caring for Millie's cancer, listed in case study on
310510 - 080110. ref SDS 24 F47O
310512 - ..
310513 - Gwen transmits report on treatments after hyperthermia at UCSF
310514 - achieves local control of Millie's IBC, and when Millie will require a
310515 - strategy for continuing treatment of cancer as a chronic disease,
310516 - shown in Millie's letter to UCSF earlier this morning on 090204 0219
310517 - calling for teamwork between Kaiser and UCSF, and between UCSF Breast
310518 - Care Clinic, and Radiation Oncology, supervised by Doctor Rugo,
310519 - ref SDS 80 278Q, and further requesting medical opinion on teatments
310520 - after hyperthermia. ref SDS 80 278T
310521 -
310522 - 1. Subject: Oncology Strategy Case Management
310523 - Date: Wed, 4 Feb 2009 16:36:31 -0800
310530 - ..
310531 - 3. Here is the final report. Please make sure you delete the
310532 - preliminary report so there are no mix-ups.
310533 -
310534 - [On 090218 0828 received follow up letter from Gwen
310535 - submitting article on Thermodox used with hyperthermia.
310536 - ref SDS 85 7Q7J
310538 - ..
310539 - 4. I look forward to our talk tomorrow!
310540 -
310541 - [On 090205 telecon consultation with Gwen. ref SDS 82 I36H
310542 -
310543 - [On 090206 Gwen notes that Millie's case is inspirational
310544 - surviving a very aggressive cancer and complex case
310545 - management for so many years. ref SDS 83 7Q7J
310546 -
310552 - ..
310553 - Attached to Gwen's letter is a report...
310554 -
310555 - [On 090205 telecon conference discussed Gwen's report.
310556 - ref SDS 82 NM4H
310558 - ..
310559 - Treatment Options Patient Profile
310560 -
310561 - This is the content of Gwen's report, ref DRT 1 0001, with some
310562 - edits for clarification...
310563 -
310564 - Gwen seems to present 5 approaches...
310565 -
310566 - A. MD Anderson 2nd opinion IBC research lab. ref SDS 0 4R3S
310567 - B. Chemotherapy clinical trials. ref SDS 0 UK62
310568 -
310569 - [On 090218 0828 received follow up letter from Gwen
310570 - submitting article on Thermodox used with hyperthermia.
310571 - ref SDS 85 7Q7J
310573 - ..
310574 - C. Vaccine clincial trials. ref SDS 0 4S3P
310575 - D. Test Tissue for most effective treatment. ref SDS 0 9K9W
310576 - E. Document/Literature/Conference review. ref SDS 0 9K5R
310577 -
310578 - 1. Diagnosis:
310579 -
310580 - a. 6th Relapse secondary inflammatory breast cancer (IBC)
310581 - January 22, 2009 Requires urgent treatment quickly to
310582 - prevent losing local control.
310584 - ..
310585 - b. ER-negative, PR-negative, HER2-negative
310587 - ..
310588 - c. Pulmonary embolism treatment wafarin (Coumadin) daily.
310590 - ..
310591 - d. Dislocated right shoulder January 22, 2009
310593 - ..
310594 - 2. Purpose 2nd Opinion
310595 -
310596 - Quality of life strategy identify treatments for cancer as
310597 - chronic disease, after hyperthermia achieves local control in
310598 - about 6 weeks. Treatments sustain qualify of life through
310599 - synergy with natural immunity.from patients lifestyle of
310600 - vigorous exercise. ref DRT 1 VK7P
310602 - ..
310603 - Aligns with the record on 090106 submitted to Stritter Consulting on
310604 - purpose of 2nd opinion. ref SDS 49 PQ6Q
310606 - ..
310607 - Millie's objective was presented to UCSF in a letter this morning on
310608 - 090204 0217. ref SDS 80 278T
310610 - ..
310611 - Stritter opinion continues...
310612 -
310613 - 3. Status:
310614 -
310615 - Begin hyperthermia with lower dose radiation scheduled February
310616 - 19, 2009 at UCSF to achieve local control by reversing
310617 - currently expanding IBC.
310619 - ..
310620 - 4. Treatments to date:, ref DRT 1 J48K
310621 -
310622 - 1. Left breast lumpectomy sentinal node disection 2002
310623 - 2. Adriamycin/Cytoxan 2002
310624 - 3. Radiation 2002
310625 - 4. Taxotere 2002
310626 - 5. Taxol/Avastin 2004
310627 - 6. Adriamycin/Cytoxan 2005
310628 - 7. Taxotere/Xeloda 2005
310629 - 8. Mastectomy 2005
310630 - 9. Taxotere/Xeloda 2006
310631 - 10. Carboplatin/Erbitux (cetuximab) 2007 and 2008
310632 - 11. Sutent/Methotrexate/Cytoxan 2008
310633 - 12. Hyperthermia with lower dose radiation 2009
310635 - ..
310636 - Aligns patient history submitted to Stritter consulting on 090106.
310637 - ref SDS 49 K87F
310639 - ..
310640 - [On 090213 1140 Millie's treatment history listed
310641 - during meeting with Doctor Johnson, Millie's primary
310642 - care physician at Kaiser. ref SDS 84 ES7I
310643 -
310645 - ..
310646 - Stritter opinion continues...
310647 -
310648 - 5. Treatment Options (generally in the order of importance)
310649 -
310650 - {supplements prior listing of treatment options proposed by
310651 - UCSF listed in the record on 090121 1017. ref SDS 58 EV53}
310653 - ..
310654 - [On 090206 Gwen notes that Millie's case is inspirational
310655 - surviving a very aggressive cancer and complex case
310656 - management for so many years. ref SDS 83 7Q7J
310657 -
310658 - a. MD Anderson IBC Research Center
310660 - ..
310661 - Evaluation and Treatment (on-site or in conjunction with
310662 - Kaiser oncologists) at the top inflammatory breast cancer
310663 - center in the country: MD Anderson Cancer Center,
310664 - Houston, TX
310666 - ..
310667 - Doctor Massimo Cristofanilli is the co-director of their
310668 - IBC clinic; 1-877-MDA-6789
310670 - ..
310671 - In December 2008, held the first ever IBC conference; if
310672 - you are interested, I could obtain the research presented
310673 - at this conference
310675 - ..
310676 - They could also give you a second opinion on the lymph node
310677 - biopsy done 11/7/08 (no appointment required usually)
310679 - ..
310680 - In 5% - 10% of cases, initial biopsy analysis will be
310681 - incorrect. Review therefore yields additional treatment
310682 - options in some cases. The patient requests the biopsy
310683 - slide from the laboratory at Kaiser, similiar to getting a
310684 - second opinion, and mail to the MD Anderson
310686 - ..
310687 - b. Participation in clinical trials (but must meet their
310688 - eligibility requirements)
310689 -
310690 - 1. Phase I/II study of GM-CSF vaccine therapy with
310691 - interferon alfa and Cytoxan; Good Samaritan
310692 - Hospital, Los Angeles, Ca; Charles Wiseman, MD;
310693 - primary investigator; contact: Cary H. Gota, MD at
310694 - 213-977-1214; Dr. Wiseman has been doing cancer
310695 - immunotherapy for many, many years
310696 -
310697 - [On 090218 0828 received follow up letter from Gwen
310698 - submitting article on Thermodox used with
310699 - hyperthermia. ref SDS 85 7Q7J
310701 - ..
310702 - [On 090220 1548 paper received from UCSF on
310703 - hyperthermia explains options combining with
310704 - chemotherapy, ref SDS 86 0129, and biological
310705 - vaccines. ref SDS 86 0164
310707 - ..
310708 - [On 090312 0830 meeting with Tara says Doctor Rugo
310709 - planning treatments for Millie after radiation and
310710 - hyperthermia. ref SDS 87 SS4F
310712 - ..
310713 - [On 090312 0830 Doctor Hsu advises UCSF Radiology
310714 - Oncology Department has more treatments that can
310715 - help Millie recover from IBC. ref SDS 87 F973
310717 - ..
310718 - [On 090326 0054 research on treating Millie's cancer
310719 - as chronic disease submitted to medical team, at
310720 - request of primary care physician. ref SDS 89 DW5S
310722 - ..
310723 - 2. Phase I/II study of Rexin-G, a viral vector oncocidal
310724 - gene therapy for breast cancer; Epeius Clinical
310725 - Research Unit; San Marino, Ca; Sant Chawla,
310726 - primary investigator; 310-552-9999; the theory
310727 - behind this vaccine is impeccable
310729 - ..
310730 - 3. Phase II study of Casodex (Bicalutamide) in
310731 - androgen receptor-positive, triple-negative BC;
310732 - Memorial Sloan-Kettering Cancer Center, NY;
310733 - Clifford Hudis, primary investigator; 212-639-5449; but
310734 - tumor must be tested for androgen-receptor first
310736 - ..
310737 - 4. Phase II study of AZD0530, a Src inhibitor for triple-
310738 - negative BC; Memorial Sloan-Kettering Cancer
310739 - Center, NY; Dr. Tiffany A. Traina, primary investigator;
310740 - 212-639-5209
310742 - ..
310743 - 5. Phase IIb study of Gemzar +/-Nexavar: Memorial
310744 - Sloan-Kettering Cancer Center, NY; Clifford Hudis,
310745 - primary investigator; 212-639-5449; Nexavar as anti-
310746 - VEGF activity like Avastin but without the blood clot
310747 - risk; of note, Nexavar is similar to but not the same
310748 - as Sutent (sunitinib used for Millie's 5th relapse
310749 - beginning on November 13, 2008, and ended on January
310750 - 22, 2009)
310752 - ..
310753 - 6. Phase 1 study of PARP inhibitor; this drug is showing
310754 - exciting activity against BRCA-positive tumors (most
310755 - BRCA+ tumors are triple negative); multiple studies in
310756 - multiple locations:
310757 -
310758 - • National Cancer Insitute, Bethesda, MD;
310759 - clinicaltrials.gov identifier NCT00749502,
310760 - NCT00553189, NCT00647062
310762 - ..
310763 - • Tampa, FL sponsored by Merck;
310764 - clinicaltrials.gov identifier NCT00749502;
310765 - contact 888-577-8839
310766 -
310767 - [On 090326 0054 research on treating Millie's
310768 - cancer as chronic disease submitted to medical
310769 - team, at request of primary care physician.
310770 - ref SDS 89 DW5S
310772 - ..
310773 - [On 090326 1733 Doctor Johnson responded in a
310774 - letter saying he plans to talk about this at the
310775 - next meeting. ref SDS 90 WR5O
310777 - ..
310778 - [On 090616 1245 Doctor Rugo reports UCSF and
310779 - Kaiser have agreed that Millie's next treatment
310780 - at UCSF after MPA will be with PARP. ref SDS 91
310781 - KD6L
310783 - ..
310784 - [On 090617 0112 Millie notifies medical team
310785 - Doctor Rugo reports everybody at Kaiser and UCSF
310786 - is "on board" to treat Millie's cancer as a
310787 - chronic disease, ordered by Doctor Johnson, and
310788 - the next treatment after MPA will be PARP
310789 - targeted to Millie's patient profile. ref SDS 92
310790 - VS9P
310792 - ..
310793 - [On 090716 2106 Millie notifies medical team that
310794 - UCSF delayed starting Millie's treatment with
310795 - PARP until September, because Millie suffered
310796 - painful breathing that might be caused by MPA so
310797 - this treatment ended before PARP protocol was
310798 - ready in September. ref SDS 93 EE6P
310800 - ..
310801 - [On 090909 Doctor Johnson advised that his
310802 - schedule had cleared to have enough time for
310803 - reviewing treatment options submitted on 090326,
310804 - and providing analysis comparing trade-offs in
310805 - order to prescribe treatment with the best chance
310806 - of being effective. ref SDS 94 VF60
310808 - ..
310809 - [On 090922 0810 Millie asks medical team about
310810 - progress starting PARP, and review of other
310811 - targeted therapies. ref SDS 95 NW6S
310813 - ..
310814 - [On 091027 0830 Doctor Johnson disclosed that
310815 - there still has not been enough time to review
310816 - follow on treatments for Millie, and that he has
310817 - not heard from Doctor Rugo on UCSF's progress
310818 - starting the PARP protocol. ref SDS 96 GN5G
310820 - ..
310821 - [On 100112 0830 Doctor Johnson reviews published
310822 - guidance on 2nd opinion PARP therapy targeted to
310823 - treat Millie's cancer with triple negavie patient
310824 - profile. ref SDS 97 N586
310826 - ..
310827 - 7. Phase I study of CNF2024, an oral HSP 90 inhibitor;
310828 - Memorial Sloan-Kettering Cancer Center, NY ; Dr.
310829 - Shanu Modi, primary investigator; 212-639-5243
310831 - ..
310832 - 8. Phase I study of Vaccinia virus injection into
310833 - superficial tumors; University of Pittsburgh Cancer
310834 - Institute; Herbert J. Zeh, MD, PhD, primary
310835 - investigator; 412-692-2852 or zehh@upmc.edu
310837 - ..
310838 - c. Vaccine clinical trials - new immunotherapy programs
310839 -
310840 - 1. Phase I study of dendritic cell vaccine; Southern
310841 - Cancer Center, Mobile, AL; Paul Schwarzenberger,
310842 - MD, primary investigator; contact Judy Motlow
310843 - 251-433-9899
310845 - ..
310846 - 2. Phase I study of mammaglobin-A DNA vaccine;
310847 - Washington University; St. Louis, MO; primary
310848 - investigator is William Gillanders, M.D. at 314-7470072
310849 - or gillandersw@wustl.edu; very exciting
310850 - possibility but not quite recruiting yet
310852 - ..
310853 - 3. Phase I trial of Ad-sig-hMUC-1/ecdCD40L vaccine;
310854 - Jonsson Cancer Center, UCLA; Sara Hurvitz, MD
310855 - primary investigator; 888-798-0719; very exciting as
310856 - Millie's cancer is very likely to MUC-positive since it is
310857 - CA 15-3 positive
310859 - ..
310860 - 4. Phase II study of vaccine with Aldesleukin; University
310861 - of Minnesota; Tufia Haddad, MD, primary
310862 - investigator; 612-624-2620
310864 - ..
310865 - 5. Phase 1 study of CDX-1307 and hCG-B vaccine;
310866 - Duke University, Durham, NC: Micheal Morse, MD,
310867 - primary investigator; contact Nikki Adams, RN at
310868 - 313-916-8862; University of Pennsylvania,
310869 - Philadelphia, PA; Angela DeMichelle, MD, primary
310870 - investigator; contact Adri Recio, RN at 215-573-6760
310871 - Novel therapy outside of clinical trials (using interventions
310872 - with at least some clinical data support):
310874 - ..
310875 - 6. Autologous vaccine (made from the patient's live
310876 - tumor); Gustavo Moviglia, MD; main lab: Buenos
310877 - Aires, Argentina; also has facilities in San Salvador;
310878 - not covered by any U.S. insurance; expensive
310880 - ..
310881 - d. Test Tissue for Most Effective Treatment, ref DRT 1 G26K
310882 -
310883 - 1. Chemosensitivity testing of live tumor to determine
310884 - which chemotherapy or targeted agent is most
310885 - active against the tumor; Rational Therapeutics;
310886 - Robert Nagourney, MD, medical director; contact
310887 - Shari Burt at (562) 989-6455 x103
310889 - ..
310890 - Previously, on 061201 considered tissue testing to evaluate most
310891 - effective cancer treatment. ref SDS 19 KT7J
310893 - ..
310894 - 2nd Opinion continues...
310895 -
310896 - 2. Molecular profile of tumor using paraffin-preserved
310897 - tissue from previous biopsy or fresh live tumor; this
310898 - test may help you find the cancer's Achilles heel;
310899 - Caris/Molecular Profile Institute; (602) 358-8900; ask
310900 - about their program where they don't charge you
310901 - even if your insurance company won't cover it
310903 - ..
310904 - e. Document/Liturature/Conference Review, ref DRT 1 444G
310905 -
310906 - 1. San Antonio Breast Cancer Conference 12/2008;
310907 - Abstract #2119 from MD Anderson; clomipramine, a
310908 - commonly prescribed anti-depressant, targets the
310909 - protein GSTpi which is found consistently and in high
310910 - concentrations on triple-negative breast cancer cells
310912 - ..
310913 - 2. San Antonio Breast Cancer Conference 12/2008;
310914 - Abstract #3118 from MD Anderson; datasinib
310915 - showed single-agent activity in women with
310916 - advanced triple-negative breast cancer
310918 - ..
310919 - 6. ***Please note above research assumes the cancer is HER2
310920 - negative. The definitive test result (a FISH analysis done on
310921 - the lymph node biopsy of 11/7/08) was not noted in the records.
310922 - ref DRT 1 355K
310924 - ..
310925 - Doctor Damen submitted documented confirmation of HER2 negative from
310926 - biopsy on 081107 with her letter on 081202. ref SDS 38 FG5G These
310927 - results are listed in the record of Millie's patient history submitted
310928 - to Gwen on 090106. ref SDS 49 SW6O
310929 -
310930 -
310931 -
310932 -
310933 -
310934 -
310935 -
310936 -
310937 -
310938 -
310939 -
3110 -